Rezorstobart

瑞佐苏拜单抗

Report date: 2024/01/04 14:48:38

Base Information

Drug NameRezorstobart
Drug Alias NameIMT-009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionKiller cell lectin-like receptor subfamily B member 1 inhibitorsNatural killer cells modulators
TargetsKiller cell lectin-like receptor subfamily B member 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsIntestinal Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmunitas Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunitas Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsIntestinal Neoplasms +[12] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A